The U.S. Food and Drug Administration approved two additional doses of Eli Lilly and Company’s Trulicity (dulaglutide).

The U.S. Food and Drug Administration approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte, but declined to approve its higher and more lucrative dose.

The U.S. FDA approved two doses of Pfizer Inc.’s medicine Xeljanz for treating active psoriatic arthritis.